• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Keywords » opioid use disorder

Items Tagged with 'opioid use disorder'

ARTICLES

Research Update

Long-Term Patient Outcomes with Buprenorphine for Opioid Use Disorder

January 1, 2025
Peter J. Farago, MD.
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Peter Farago, MD. Dr. Farago has no financial relationships with companies related to this material.

Researchers compare outcomes in patients who take buprenorphine for shorter and for longer. Their findings are revealing.


Read More
Clinical Update

Effective Management of Buprenorphine-Precipitated Opioid Withdrawal

January 1, 2025
Jaewon Lee, MD, MPH
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Jaewon Lee, MD, MPH. PGY-2, psychiatry resident, University of Rochester Medical Center, Rochester, NY. 

Dr. Lee has no financial relationships with companies related to this material.

Buprenorphine is a first-line treatment for opioid use disorder, however, given buprenorphine to a patient who still has opioids in their system can precipitate severe withdrawal. Careful assessment of withdrawal can minimize the risk, but despite our best efforts, precipitated withdrawal can still occur. In this article, we review what to do for our patients experiencing buprenorphine-precipitated opioid withdrawal.


Read More
Research Update

Rapid Initiation of Extended-Release Buprenorphine

October 1, 2024
Aniruddha Deka, MD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Aniruddha Deka, MD. Dr. Deka has no financial relationships with companies related to this material.

Long-acting buprenorphine is a promising new treatment for opioid use disorder, but it usually requires a seven-day stabilization period before initiation. Here, researchers develop and evaluate a novel protocol for initiating long-acting injectable buprenorphine in a single day. The trial is small, but results are promising.


Read More
TCPR-Oct2024_QA_NCapurso headshot.png
Clinical Update

A New Era for Buprenorphine

September 26, 2024
Noah Capurso, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

TCPR-Oct2024_QA_NCapurso headshot.pngNoah Capurso, MD, MHS.

Associate Professor of Psychiatry, Yale University, New Haven, CT; Editor-in-Chief, The Carlat Addiction Treatment Report.

Dr. Capurso has no financial relationships with companies related to this material.

A buprenorphine boot camp for all who need to know how to use it in the post-X-waiver age.


Read More
Clinical Update

Post X-Waiver Buprenorphine Prescribing

September 26, 2024
Noah Capurso, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Noah Capurso, MD, MHS. Associate Professor of Psychiatry, Yale University, New Haven, CT; Editor-in-Chief, The Carlat Addiction Treatment Report.

Dr. Capurso has no financial relationships with companies related to this material.

All clinicians need to know how to use buprenorphine under the DEAs new regulations. Meanwhile, the fentanyl crisis is changing how we use it. Noah Capurso shows us how to navigate these waters.


Read More
Research Update

Buprenorphine Versus Methadone for Opioid Use Disorder in Pregnancy

July 1, 2024
Richard Moldawsky, MD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Richard Moldawsky, MD. Dr. Moldawsky has no financial relationships with companies related to this material.

Buprenorphine and methadone are both first-line treatments for opioid use disorder during pregnancy. Though this recommendation has been long-standing, it is based on a rather small study that is nearly 15 years old. In the current study, researchers revisit the question of how best to treat opioid use disorder during pregnancy with a large observational cohort study.


Read More
gavel_AlexStaroseltsev_shutterstock_404793811.jpg
Expert Q&A

Opioid Use Disorder in Correctional Facilities

July 1, 2024
Elizabeth Needham Waddell, PhD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

CATR_QA2-Elizabeth-Needham-Waddell_headshot.jpgElizabeth Needham Waddell, PhD. 

Associate Professor, OHSU-PSU School of Public Health & Section of Addiction Medicine, Division of General Internal Medicine, Oregon Health & Science University, Portland, OR.

Dr. Waddell has no financial relationships with companies related to this material.

People with opioid use disorder who are incarcerated have an elevated rate of morbidity and mortality, particularly following release.


Read More
Research Update

Opioid Use Disorder Treatment During the Peripartum Period

April 1, 2024
Gregory Nikogosyan, DO
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Gregory Nikogosyan, DO. Dr. Nikogosyan has no financial relationships with companies related to this material.

The last high-quality head-to-head comparison of buprenorphine and methadone during pregnancy was the MOTHER trial, which was published nearly 15 years ago. Here, researchers revisited the question of which medication is better to use in pregnancy in this large, carefully done, retrospective study. The results make a compelling case for buprenorphine. 


Read More
Research Update

Extended-Release Buprenorphine for Opioid Use Disorder in Correctional Settings

February 1, 2024
Eli Neustadter, MD, MSc.
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Eli Neustadter, MD, MSc. Dr. Neustadter has no financial relationships with companies related to this material.

Incarcerated individuals with opioid use disorder are at an especially heightened risk of adverse outcomes.  The period immediately following release is a particularly vulnerable time, with a much elevated risk of fatal overdose. In this study, investigators report on the use of extended-release injectable buprenorphine in a correctional setting.


Read More
Research Update

Perinatal MOUD Use and Infant Discharge to Biological Parents

October 31, 2023
Destiny Pegram, MD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Destiny Pegram, MD. Dr. Pegram has no financial relationships with companies related to this material.

Pregnant patients with OUD may be reluctant to reveal their substance use for fear of losing their baby if reported to Child Protective Services. But this recent study shows that pregnant patients receiving medication treatment for OUD were more likely to leave the hospital with their baby than patients not receiving treatment.


Read More
More Articles Tagged with 'opioid use disorder'
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2603816031.jpg
    General Psychiatry

    A Scam for Every Woman, Child, and Man: Part 2

    1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.